All In Biotech

Drug Trial Radar · NCT04133909

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 806 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

806

Actual

Start

Oct 30, 2019

Primary completion

Aug 8, 2024

Study completion Aug 8, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
PPD Development, LP
First posted
Oct 21, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study designed to confirm the benefits of mepolizumab treatment on moderate or severe exacerbations in chronic obstructive pulmonary disease (COPD) participants given as an add on to their optimized maintenance COPD therapy. The maximum duration of participant participation is approximately 109 weeks, consisting of 2 screening visits (up to 3 weeks), a run-in period (up to 2 weeks), and an intervention period of at least 52 weeks and up to 104 weeks. 800 participants will be randomized in a 1:1 ratio to receive mepolizumab 100 milligrams (mg) or placebo every 4 weeks for at least 13 doses (52 weeks treatment period) up to a maximum of 26 doses (104 weeks treatment period). The number of randomized participants may increase up to approximately 1400.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • MepolizumabBiological

    Mepolizumab was a sterile liquid formulation. It was administered as a subcutaneous injection (100 milligrams per milliliter \[mg/mL\]) delivered once every 4 weeks using a pre-filled safety syringe.

  • PlaceboDrug

    Placebo was a 0.9% sodium chloride solution. It was administered as a subcutaneous injection delivered once every 4 weeks using a pre-filled safety syringe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Moderate or Severe ExacerbationsTime frame: Up to Week 104

Locations

339 sites in 26 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Dothan, Alabama

  • GSK Investigational Site

    Huntsville, Alabama

  • GSK Investigational Site

    Jasper, Alabama

  • GSK Investigational Site

    Chandler, Arizona

  • GSK Investigational Site

    Chandler, Arizona

  • GSK Investigational Site

    Gilbert, Arizona

  • GSK Investigational Site

    Mesa, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Conway, Arkansas

  • GSK Investigational Site

    Alpine, California

  • GSK Investigational Site

    Cerritos, California

  • GSK Investigational Site

    Newport Beach, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Torrance, California

  • GSK Investigational Site

    Vista, California

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Boynton Beach, Florida

  • GSK Investigational Site

    Clearwater, Florida

  • GSK Investigational Site

    Daytona Beach, Florida

  • GSK Investigational Site

    Doral, Florida

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Homestead, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami Lakes, Florida

  • GSK Investigational Site

    Miami Lakes, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Pinellas Park, Florida

  • GSK Investigational Site

    Plantation, Florida

  • GSK Investigational Site

    Port Orange, Florida

  • GSK Investigational Site

    St. Petersburg, Florida

Showing 40 of 339 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.